KRTAP25-1 Inhibitors
KRTAP25-1 inhibitors form a diverse class of chemicals targeting specific signaling pathways crucial for the activation of KRTAP25-1. These inhibitors act at various points in the molecular cascade, disrupting phosphorylation events and protein-protein interactions necessary for KRTAP25-1 functionality. Trametinib and SB202190 inhibit MEK and p38 MAP kinase, respectively, disrupting the MAPK/ERK and p38 MAP kinase pathways associated with KRTAP25-1 activation. LY294002 and Wortmannin target PI3K, affecting the PI3K/Akt pathway, while AZD8055 inhibits mTOR, influencing the downstream events linked to KRTAP25-1. VX-11e and NSC 23766 disrupt JAK2 and Rac1, affecting pathways related to KRTAP25-1 activation. A769662 activates AMPK, negatively regulating mTOR, indirectly inhibiting KRTAP25-1. Additionally, SP600125, PF-562271, and SP010 target JNK, FAK, and Akt, respectively, interfering with cellular processes crucial for KRTAP25-1 function. This chemical class, by precisely targeting key cellular pathways, provides a versatile toolkit for investigating and modulating KRTAP25-1 functionality at the molecular level.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib inhibits MEK, a kinase in the MAPK/ERK pathway associated with KRTAP25-1 activation. Its action disrupts downstream events, suppressing KRTAP25-1 functionality. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 targets PI3K, an upstream molecule in the PI3K/Akt pathway linked to KRTAP25-1 signaling. Inhibiting PI3K disrupts the activation of KRTAP25-1, impacting its functionality. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB202190 inhibits p38 MAP kinase, a protein involved in pathways related to KRTAP25-1. Its action disrupts the downstream events associated with KRTAP25-1 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, disrupting the PI3K/Akt pathway associated with KRTAP25-1. By inhibiting PI3K, it interferes with the activation of KRTAP25-1, impacting its function. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 inhibits mTOR, a key player in the PI3K/Akt/mTOR pathway associated with KRTAP25-1 activation. Its action disrupts the pathway, suppressing KRTAP25-1 functionality. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
VX-11e inhibits JAK2, affecting pathways linked to KRTAP25-1 activation. By disrupting JAK2, it interferes with the signaling cascade, leading to inhibition of KRTAP25-1. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A769662 activates AMPK, negatively regulating mTOR, a pathway associated with KRTAP25-1. Its action indirectly inhibits KRTAP25-1 by disrupting the mTOR-mediated activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a kinase associated with various cellular processes. Inhibition of JNK disrupts signaling pathways related to KRTAP25-1, affecting its functionality. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
PF-562271 inhibits FAK, disrupting the FAK/PI3K/Akt pathway linked to KRTAP25-1 activation. Its interference with this pathway leads to inhibition of KRTAP25-1 functionality. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC 23766 inhibits Rac1, affecting pathways linked to KRTAP25-1 activation. By disrupting Rac1, it interferes with the signaling cascade, leading to inhibition of KRTAP25-1. | ||||||